Quote. These are my principles. If you don t like them I have others. Groucho Marx

Similar documents
Maternal vaccination

Measles Elimination in NZ. Dr Tom Kiedrzynski Principal Adviser, Communicable diseases, Ministry of Health

Under-immunisation in migrant communities: the measles outbreak in southwestern

Global and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office.

Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox

Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox

Measles Update. March 16, 2015 Lisa Miller, MD, MSPH Communicable Disease Branch Chief Lynn Trefren MSN, RN Immunization Branch Chief

Measles Elimination Dr. Suzanne Cotter 4 th National Immunisation Conference 2007

MICHAEL PARK A RUDOLF STEINER SCHOOL

MEASLES HEALTH ALERT/ADVISORY. Date: February 5, Dear Colleague:

HEALTH ADVISORY: MEASLES EXPOSURES IN NEW YORK STATE

MEASLES. Tracey Johnson Infection Control Specialist Nurse

Measles: United States, January 1 through June 10, 2011

Immunisation Update for Occupational Health

Epidemiologic Characteristics of Recent Measles Outbreaks in ROK

Measles and Measles Vaccine

Elizabeth Hinson ID Homework #2

Immunization-Preventable Outbreaks, Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Health Care Agency May 5, 2014

NYS Trends in Vaccine Preventable Disease Control

Elizabeth Tenney Infectious Disease Epidemiology Homework 2 Texarkana Epidemic Measles in a Divided City Question 1a: Any outbreak of measles is cause

Health Professionals Advice: Pertussis 7 June, 2012

Measles is a highly infectious viral

5/13/2015 TODAY S TOPICS SURVEILLANCE, REPORTING AND CONTROL OF VACCINE PREVENTABLE DISEASES 2015

keyword: hepatitis Hepatitis

Measles 2015: What We Need to Know

Closing MR Immunity Gaps Experiences from the Regions Sri Lanka

Why is surveillance important after introducing vaccines?

Monitoring vaccine-preventable diseases is

Chapter 6: Measles. I. Disease description. II. Background

Introduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa

BCCDC Measles, Mumps and Rubella Enhanced Surveillance Case Report Form

Prevent Measles Example of Fact sheet for health workers in Fiji

It IS a Small World After All: The Public Health Impact and Immunologic Assessment of a Disneyland Measles Case in El Paso County, Colorado

PERTUSSIS. Introduction

Sensitivity and Positive Predictive Value of the Measles Surveillance System In Uganda,

Measles is a highly infectious disease caused by

Measles and rubella monitoring January 2015

Update on Mumps and Current Status of Outbreak in NW Arkansas

Measles Makes a Comeback Epidemiology and Laboratory Testing

DISCLOSURES. I have no actual or potential conflicts of interest in this presentation.

Pertussis Outbreak Investigation Report. Office of the Chief Medical Officer of Health

Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive)

Measles, Mumps, and Pertussis. UALBH Annual Symposium September 8, 2017 Gary Edwards, Executive Director

Rubella rev Jan 2018

Measles. Paul R. Cieslak, MD Public Health Division February 7, 2019

VII THE CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE 7. 7

Wisconsin physicians, other clinicians, infection control professionals, local health department directors in Wisconsin

Don t let your child catch it

Guidance for the Control of Measles Incidents and Outbreaks in Scotland. Scottish Health Protection Network Scottish Guidance No 4 (2018 edition).

NSW Annual Vaccine-Preventable Disease Report, 2009

Measles, Mumps and Rubella. Ch 10, 11 & 12

VACCINE-PREVENTABLE DISEASES (VPDS): CURRENT TRENDS

5/4/2018. Describe the public health surveillance system for communicable diseases.

VACCINE PREVENTABLE DISEASE EPIDEMIOLOGY

Measles Redux FEBRUARY 26, Karen Holbrook, MD MPH Deputy Health Officer

World Health Organization, Western Pacific Regional Office, Manila, Philippines Issue 13 September 2007 ISSN

An ongoing large outbreak of measles in Merseyside, England, January to June 2012

Immunisation coverage How much do we need? How do we get there?

Measles Surveillance in the United States: An Overview

NSW Annual Vaccine-Preventable Disease Report, 2011

Today s Presentation

Adult and Pediatric Immunization Updates May 2018 Kathryn Sen, RN, BSN Bureau of Immunization Vaccine Preventable Disease Surveillance Officer

Dr Tara Anderson ACIPC 24 th November 2015

Table 1. Measles case classification and incidence by country and area, WHO Western Pacific Region,

Epidemiology and Control of Pertussis in England: Impact of Maternal Immunisation Dr Gayatri Amirthalingam

PERTUSSIS REPORT. November 2013

Measles rev Jan 2018

Policy Document. Vaccination Policy. Background

Impact and effectiveness of national immunisation programmes. David Green, Nurse Consultant, Immunisations Public Health England

Guidelines for Control of Measles in Ireland

Measles in Ireland, 2005

HEALTH PROFESSIONAL ADVICE: Pertussis (update March 2014)

California 2010 Pertussis Epidemic. Kathleen Winter, MPH Immunization Branch California Department of Public Health

Varicella Epidemiology and Testing. Lexie Barber Varicella Epidemiologist November 2, 2018

Appendix B: Provincial Case Definitions for Reportable Diseases

The HPV Immunisation Programme in NZ. Chris Millar Senior Advisor Immunisation Ministry of Health

Don t let your child catch it

Hepatitis B from targeted screening and immunisation of migrant mothers to universal immunisation in Australia

New guidelines for the management of norovirus outbreaks in acute and community health and social care settings

Dengue... coming to a town near you. Amanda Hutchings Senior Environmental Health Officer Darling Downs Public Health Unit

Infectious Disease Surveillance in NZ. Michael Baker Department of Public Health, University of Otago, Wellington

Framework for Verifying Elimination of Measles and Rubella SAGE Working Group on Measles and Rubella (Draft of 18 October 2012)

Total population 20,675,000. Live births (LB) 349,715. Children <1 year 346,253. Children <5 years 1,778,050. Children <15 years 5,210,100

Measles (Rubeola) Biology of measles virus. April 20, 2017 Department of Public Health Sciences

Health Professionals Advice: Summer

Spotlight on measles 2010: A cluster of measles in a hospital setting in Slovenia, March 2010

Measles & rubella outbreaks in Maharashtra State, India

Steps toward Measles Eradication in Japan A report from Okinawa Prefecture

Immunity and how vaccines work

The pages that follow contain information critical to protecting the health of your patients and the citizens of Colorado.

Module on best practices for measles surveillance

EPIDEMIOLOGY OF VACCINE-PREVENTABLE VIRAL INFECTIONS IN ABORIGINAL & TORRES STRAIT ISLANDER AUSTRALIANS

MUMPS & MEASLES: WHAT WE VE LEARNED FROM RECENT OUTBREAKS

An aggressive approach for measles outbreak among adolescents in Barranquilla, Colombia, 2011

The Virtual Immunization Communication (VIC) Network is a project of the National Public Health Information Coalition (NPHIC) and the California

MEASLES, MUMPS, RUBELLA (MMR)

Questions & Answers 1 November 2005 Vaccine Schedule

What s happening in NZ with influenza

Vaccination Lets work together. Presentation Outline. How vaccines work 22/08/2018. Dr Fiona Ryan IPC Course September 2018.

Transcription:

Quote These are my principles. If you don t like them I have others. Groucho Marx

Analysis of the Auckland 2014 Measles Outbreak Indicates that Adolescents and Young Adults could Benefit from Catch up Vaccination. Gary Reynolds, Cassandra Dias, Simon Thornley, Ronald King, Angela Matson, Anne Morrison & Richard Hoskins In Press NZ Medical Journal Auckland Regional Public Health Service, Private Bag 92605, Symonds Street, Auckland 1150, New Zealand

Measles Outbreak Auckland, NZ 2014 December 2013 to June 2014 Epidemiology Immunology Vaccinology Aim : To analyse the Measles 2014 outbreak in Auckland to guide future preventive measures

A contagious disease Source: http://www.healthline.com/health/r nought reproductionnumber#conditions4

Background Measles is highly contagious (Ro = 12 18) Burden of disease in developing countries Declined markedly in western countries after mass vaccination campaigns with MMR 45 years of MMR vaccine measles and its complications still persist Australia (But not NZ) is declared by WHO measles free Notifiable in NZ since 1996

Imported measles common

The MMR Highly efficacious and safe vaccine Live vaccine so no boost required Second dose improves efficacy from 90 to 95% NZ schedule 15 months and 4 years Under 1 year interference circulating maternally derived antibodies Modeling shows over 95% coverage required to eliminate disease Historical unjustified controversy since 1998

Methods The setting Auckland (1.4 million) Essentially Indigenous Measles free The Method All Measles Notifications go to Public Health Services Each notification is assigned to PH Nurse Collect clinical information, immunisation history and immune status

Methods: The diagnosis of Measles Confirmed Probable Under investigation Not a case Laboratory results consistent with measles OR Fever 38 0 C and a generalised maculopapular rash and: cough or coryza or conjunctivitis or Koplik s spots and link to confirmed case Fever 38 0 C and a generalised maculopapular rash and: cough or coryza or conjunctivitis or Koplik s spots Note: No link to confirmed case Lab work not needed All measles notifications with outstanding diagnostic lab results No clinically compatible illness OR Laboratory results not consistent with measles infection OR Diagnosed vaccine reaction

Methods Outbreak coordination Initiated case management Contact tracing (Waiting rooms, schools, sport clubs, flights) Management of households Identified high risk contacts of cases Quarantine, Self isolation, Prophylaxis (Active and Passive Immunisation) as appropriate

Methods Laboratory analysis PCR if symptoms in the first 5 days Thereafter serology (anti measles IgM and IgG detection) Purely qualitative detection of anti measles IgM and IgG Serology was also requested for exposed contacts to establish immune status 1 sample from each linked chain of transmission genotyped (National Measles Lab)

Statistical Analysis Vaccine effectiveness (VE) was calculated using the screening method (Gail) Vaccine effectiveness=1 odds(vaccinated case) odds(vaccinated non case) Where: odds(vaccinated case) is the odds of being vaccinated against measles, among cases. odds(vaccinated non case) is the odds of being vaccinated against measles, in the general population.

Results First case visited Sydney Later Genotyped and linked to a traveller to same international camp in the Philippines Total 113 Cases in the Auckland region 13 of which were imported cases 9 had travelled to the Philippines 16/18 local cases linked to known imported cases 82 (73%) were linked to either sporadic or imported cases

The number of measles cases overseas and locally acquired in the 2014 Auckland outbreak showing a local peak in March 2014. There is a temporal seeding of local cases from people travelling to New Zealand from overseas Jan Feb Mar Apr May Jun Overseas Local 50 40 30 Count 20 10 0 Jan Feb Mar Apr May Jun Month (2014)

Results Cases peaked in March 2014 Temporal seeding of local cases from overseas Majority of cases occurred in adolescents and young adults 41/113 (36.3%) in 15 19 year age group 27/113 (23.4%) in 10 14 year age group

The numbers of confirmed and probable measles cases overseas and locally acquired by age, showing peaks in the under 1 and adolescent age groups. 0 10 20 30 40 40 Overseas Local 30 Count 20 10 0

Results Among cases 44/113 (38.9%) occurred in the unimmunised 36/113 (31.8%) unknown immune status 16/113 (14%) occurred in infants too young to vaccinate 17/113 (15%) had received one or two doses of vaccine

2014 Surveillance Year Measles Cases by Immunisation Status Confirmed and Probable Cases only 100% 90% 80% 70% 60% 50% 40% 30% 20% Unknown / Uncertain Unimmunised Too young First MMR post exposure Age appropriately immunised (1 dose) Age appropriately immunised (2 doses) 10% 0% Age appropriately immunised Unimmunised Extract Date: 1/07/2014 Source: NDCMS Index Case records

Incidence by age & ethnic group Incidence rate (per 100,000) 30.0 25.0 20.0 15.0 10.0 5.0 European or Other ethnicity Maori Pacific peoples Asian 0.0 0 to 4 5 to 14 15 to 24 25 to 44 45 to 64 Age category (years)

Results Of the total cases 26/113 (23%) required hospital treatment Secondary cases linked by contact at 1 school (n=37) Household contact (n=29) Social contacts (n=8) Primary care (n=3) Hospital (n=5)

Results Contacts 3113 Contacts were traced by ARPHS Immune status established by Documented 2x MMR vaccination history Or proven Serology n= 2,594 Highest non immune gp was under 1 year olds 68/75 ; 90.7%) Non immune 20 29 year olds (60/ 325; 18.5%) Non immune 15 19 year olds (28/186; 15.1%) Non immune 10 14 year olds (22 /149; 14.8%)

Results Contacts Contacts underwent serological (IgG) testing N= 737 Tested negative median age 27.4 Tested equivocal median age 26.6 Tested positive median age 34.0 Serological immunity lower in people aged 10 24 years

Proportion of tested exposed contacts who were either serologically immune or equivocal, by age (n=737; 597 positive, 57 equivocal and 83 negative). 1.00 p g y q 0.75 0.50 0.25 0.00 < 1 1 to 4 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 39 40 plus Age group (years)

Serological testing of contacts Proportion immune or equivocal 1.00 p g y q 0.75 0.50 0.25 0.00 < 1 1 to 4 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 39 40 plus Age group (years)

The contacts Proportion of exposed contacts who were assessed as immune Proportion of Immune Exposed Contacts 100 90 80 70 60 50 40 30 20 10 0 Exposed contacts with assessed immune status showing 95% Confidence Intervals and total number in each group 101 247 203 163 240 455 475 465 779 <1 1 to 4 5 to 9 10 to 14 15 to 19 20 to 29 30 to 39 40 to 49 +50 Age Group Extract Date: 1/07/2014 Source: NDCMS Exposed Contacts records

Vaccine Effectiveness Calculation 60/113 (53%) Unimmunised 16 were less than 15 months (too young) 44 known unimmunised 36 unknown vaccine status Prevalance of vaccination 90% VE if 36 unknown vaccinated = 89% VE if 36 unknown unvaccinated = 98% VE Range = 89 98%

Discussion Adolescents are susceptible So are the under 1 year olds MOH figures 400,000 in NZ from a population of 4 million (10%) The MMR vaccine is safe and effective 89 98% Reasons previous poor uptake due to safety concerns and structural issues with delivery Effective cold chain did not start until 2004 in NZ?waning immunity low immunity without natural boosting

Limitations of this Analysis It is only one part of an outbreak Countrywide 280 cases Relative small numbers affecting power Lack of Quantitative Serology Analysis

Conclusion Rapid expansion of Outbreak likely due to Unimmunised European adolescents and young adults in a close contact environment school Measles is highly contagious nature of disease Outbreaks will likely continue until coverage is improved in at risk groups (up to 30 years) Most secondary cases occurred at school and were bought home

Recommendations Early prompt reporting Check all adolescence have 2x recorded MMR?Use of Dose 0 for under 1 year olds? A targeted Catch up campaign

Acknowledgements Richard Hoskins Simon Thornley Cassandra Dias Angela Matson Anne Morrison Ronald King Staff at ARPHS